Mankind Pharma in-licenses Ensartinib from Betta Pharmaceuticals
4 Articles
4 Articles
Mankind Pharma secures India rights for Ensartinib
Mankind Pharma has entered into an in-licensing agreement with Betta Pharmaceuticals for Ensartinib, a novel, patented oncology drug approved by the US Food and Drug Administration (US FDA) and China’s National Medical Products Administration (NMPA). The drug is indicated for adult patients with anaplastic lymphoma kinase (ALK)-positive, locally advanced or metastatic non-small cell lung cancer (NSCLC) […] The post Mankind Pharma secures exclusi…
Mankind Pharma in-licenses Ensartinib from Betta Pharmaceuticals
New Delhi, November 16, 2026: Mankind Pharma has entered into an in-licensing agreement with Betta Pharmaceuticals to obtain exclusive rights for the development, manufacturing, registration and commercialisation of Ensartinib in India, the company announced. Ensartinib is a patented oncology drug approved by both the US Food and Drug Administration (FDA) and China’s National Medical Products […]
Mankind Pharma Enters into In-Licensing Agreement with Betta Pharmaceuticals for an Exclusive License in India of Novel Oncology Drug Ensartinib - Press Network of India
Bengaluru : Mankind Pharma, one of India’s leading pharmaceutical companies, has entered into an in-licensing agreement with Betta Pharmaceuticals for Ensartinib, a novel, patented oncology drug approved by the US Food and Drug Administration (US FDA) and China’s National Medical Products Administration (NMPA). The drug is indicated for adult patients with anaplastic lymphoma kinase (ALK)-positive, […]
Coverage Details
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium



